Role of the Pharmaceutical Benefits Scheme (PBS) in the Australian pharmaceutical market

Alshayban, Dhfer Mahdi (2010). Role of the Pharmaceutical Benefits Scheme (PBS) in the Australian pharmaceutical market Master's Thesis, School of Economics, The University of Queensland.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Alshayban_Dhfer_Masters.pdf Full text application/pdf 13.98MB 3
Author Alshayban, Dhfer Mahdi
Thesis Title Role of the Pharmaceutical Benefits Scheme (PBS) in the Australian pharmaceutical market
School, Centre or Institute School of Economics
Institution The University of Queensland
Publication date 2010
Thesis type Master's Thesis
Supervisor Sukhan Jackson
Total pages 87
Language eng
Subjects 140208 Health Economics
1117 Public Health and Health Services
Formatted abstract
The Pharmaceutical Benefits Scheme (PB S), along with Medicare, is a key component of Australia's health system. The PBS is a universal prescription drug scheme of the Commonwealth government, and is considered to be monopsonist because it is the only major drug buyer in Australia. In terms of equity, the PBS provides all Australians who need prescription medicines with access to essential and life saving medicines at affordable prices. It has been reported that Australian drugs are as much as 160 per cent cheaper than those in other countries such as the USA. However, the PB S is one of the fastest growing components of the Australian Health System, and there are concerns for the sustainability of the PBS and the willingness to pay of both the government and consumers. Indeed, there has been an increase in government expenditure on pharmaceutical benefits since the commencement of the programme. The Australian government has implemented several policies aimed at reducing expenditure of the PBS.

Australia is the first country in the world that requires economic evaluation in support of an application for listing a new drug on its pharmaceutical benefits scheme. These requirements are supported by law, and the Pharmaceutical Benefits Advisory Committee (PBAC) must consider the costs and effectiveness when giving its recommendations to the Minister for Health for listing a new pharmaceutical. However, cost-effectiveness requirements are not meant to contain the rising cost of pharmaceuticals, as they mainly address efficacy and efficiency issues. On the other hand, reference pricing is the important policy that is being used in Australia to contain the cost of new medicines. According to this method, the reimbursement price for a clinically equivalent group of medicines is set in relation to the price of the cheapest medicine in the group. Therefore, reference pricing has contributed to decreasing the price of drugs, in particular the "me too " drugs. However, the main drawbacks are that reference pricing allows the prices of the older drugs to remain unchanged, since all therapeutic prices are driven to the same price and also reference pricing cannot be used for the new innovation drugs because of the absence of comparable drugs.
Keyword Pharmaceutical Benefits Scheme
Australian health care system

Citation counts: Google Scholar Search Google Scholar
Created: Mon, 18 May 2015, 14:54:34 EST by Ms Christine Heslehurst on behalf of Scholarly Communication and Digitisation Service